NEW ORLEANS, Sept. 08, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 24, 2017 to file lead plaintiff applications in a securities class action lawsuit against Dr. Reddy’s Laboratories Ltd. (NYSE:RDY), if they purchased the Company’s securities between June 17, 2015 and August 10, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Get Help
Dr. Reddy’s investors should visit us at https://www.claimsfiler.com/cases/view-dr-reddys-laboratories-ltd-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Dr. Reddy’s and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company had failed to implement an effective corporate quality control system including but not limited to its manufacturing plants and (ii) as a result of the foregoing, Dr. Reddy’s financial statements were materially false and misleading at all relevant times.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.


Bank of America's $72.5M Epstein Settlement: What You Need to Know
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 



